



Patent Application
Attorney Docket No. PC9985A

03C0
#4

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231 on this 4th day of February, 2002.

By

Elsa Djuardi

(Signature of person mailing)

Elsa Djuardi

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Y. Hashizume, et al. :

APPLICATION NO.: 09/977,621

: Examiner: Not Assigned

FILING DATE: October 15, 2001

: Group Art Unit: Not Assigned

TITLE: ARYL OR HETEROARYL FUSED
IMIDAZOLE COMPOUNDS AS ANTI-
INFLAMMATORY AND ANALGESIC
AGENTS

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the reference cited by the applicant(s), a copy of which is enclosed.

The Examiner is requested to consider carefully the complete text of this reference in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing reference.

It is requested that the reference listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: February 4 '02

Elsa Djuard
Elsa Djuard
Attorney for Applicant(s)
Reg. No. 45,963

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1417